|1.||Harris, William S: 24 articles (08/2015 - 04/2006)|
|2.||Serhan, Charles N: 15 articles (09/2015 - 03/2005)|
|3.||Calder, Philip C: 13 articles (04/2015 - 04/2003)|
|4.||Arita, Makoto: 13 articles (01/2015 - 03/2005)|
|5.||Das, Undurti N: 11 articles (10/2015 - 11/2004)|
|6.||Yokoyama, Mitsuhiro: 9 articles (01/2012 - 10/2003)|
|7.||Tisdale, Michael J: 9 articles (10/2008 - 07/2002)|
|8.||Tisdale, M J: 9 articles (02/2007 - 01/2000)|
|9.||Geleijnse, Johanna M: 8 articles (05/2015 - 04/2006)|
|10.||Saito, Yasushi: 8 articles (05/2013 - 07/2008)|
07/01/2002 - "Thus eicosapentaenoic acid may be effective in the treatment of protein catabolism in conditions other than cancer."
05/01/2001 - "The action of this proteolysis-inducing factor is attenuated by the polyunsaturated fatty acid eicosapentaenoic acid, which is also effective in preventing loss of skeletal muscle in cancer patients. "
11/01/2011 - "The aim of the study was to evaluate the efficacy of administration of a new oral powder supplement enriched with eicosapentaenoic acid compared to a standard liquid supplement in cancer patients. "
10/01/2000 - "Further trials are required to confirm the efficacy of eicosapentaenoic acid and to determine the anticachectic activity in other types of cancer."
06/01/2015 - "Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in vitro and in vivo, used along with anticancer drugs, have improved cancer treatment outcome. "
|2.||Cardiovascular Diseases (Cardiovascular Disease)
04/01/2011 - "While health agencies internationally continue to advocate for high n-6 PUFA intake combined with increased intakes of preformed n-3 long-chain PUFAs (LCPUFA) docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) to reduce the incidence of cardiovascular disease (CVD), there are questions as to whether this is the best approach. "
07/01/2015 - "Consumption of omega-3 polyunsaturated fatty acid, particularly eicosapentaenoic acid (EPA), is associated with a significant reduction in the risk of developing cardiovascular disease. "
05/14/2012 - "Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials."
07/01/2015 - "Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), known as ω-3 polyunsaturated fatty acid (PUFA), are common nutrients in daily food intake and have been shown to prevent cardiovascular disease and improve cardiac functions. "
10/01/2014 - "To minimize the risk of cardiovascular disease (CVD), most dietary guidelines have recommended consuming 500 mg/day of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) or two servings of oily fish/week. "
|3.||Schizophrenia (Dementia Praecox)
12/01/2009 - "In a previously reported double-blind, placebo-controlled trial of eicosapentaenoic acid (EPA) as supplemental treatment in 40 patients with schizophrenia, we found significant improvement in symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) compared to placebo (Emsley et al. 2002). "
05/01/2000 - "The administration of the omega-3 fatty acid eicosapentaenoic acid (EPA) to a drug-naïve patient with schizophrenia, untreated with conventional antipsychotic medication, led to a dramatic and sustained clinical improvement in both positive and negative symptoms. "
01/01/2000 - "The administration of the omega-3 fatty acid eicosapentaenoic acid (EPA) to a drug-naive patient with schizophrenia, untreated with conventional antipsychotic medication, led to a dramatic and sustained clinical improvement in both positive and negative symptoms. "
02/01/1998 - "Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid."
05/01/2000 - "Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid."
07/20/2001 - "Eicosapentaenoic acid (EPA) is effective in attenuating the increased protein catabolism in muscle in cancer cachexia, possibly due to inhibition of 15-hydroxyeicosatetraenoic acid (15-HETE) formation. "
11/01/2003 - "In cancer cachexia attenuation of the inflammatory response using eicosapentaenoic acid results in improved nutritional intake and status. "
10/01/2005 - "Clinical studies have shown that administration of eicosapentaenoic acid (EPA) to patients who have unresectable pancreatic cancer induces marked attenuation of cachexia. "
11/08/2011 - "Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia."
11/01/2011 - "The beneficial effect of eicosapentaenoic acid in cancer patients is widely described especially in relation to its role in tumour cachexia. "
03/01/2000 - "To further understand potential mechanisms underlying the protective effects of eicosapentanoic acid (EPA) against atherosclerosis, J774 macrophages were used to explore cellular responses to growth in the presence of PUFA in vitro. "
09/01/2015 - "Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis."
01/01/2015 - "Krill oil (RIMFROST Sublime®) is a phospholipid-rich oil with eicosapentaenoic acid (EPA): docosahexaenoic acid (DHA) ratio of 1.8:1. In this pilot study we determined if krill oil could favourable affect plasma lipid parameters and parameters involved in the initiation and progression of atherosclerosis. "
01/01/2015 - "Eicosapentaenoic acid (EPA), an anti-hyperlipidemic agent, is known to have antioxidative or anti-inflammatory effects, resulting in improvements in atherosclerosis. "
01/01/2012 - "We studied the association of fish and the fish-derived n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with the risk of incident AF in individuals aged 45-64 from the Atherosclerosis Risk in Communities (ARIC) cohort (n = 14,222, 27% African Americans). "
|1.||Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)
|2.||Omega-3 Fatty Acids (Omega 3 Fatty Acids)
|4.||Arachidonic Acid (Vitamin F)
|6.||alpha-Linolenic Acid (Linolenic Acid)
|7.||ethyl eicosapentaenoic acid
|8.||Fatty Acids (Saturated Fatty Acids)
|1.||Enteral Nutrition (Feeding, Tube)
|3.||Drug Therapy (Chemotherapy)